Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: May 29, 2023

CLINICAL TRIALS PROFILE FOR AZACITIDINE

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

All Clinical Trials for Azacitidine

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004062 ↗	Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer	Completed	National Cancer Institute (NCI)	Phase 1	1999-07-01	RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine. PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer.
NCT00004062 ↗	Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer	Completed	Lucille P. Markey Cancer Center at University of Kentucky	Phase 1	1999-07-01	RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine. PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer.
NCT00004871 ↗	Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome	Completed	National Cancer Institute (NCI)	Phase 1	2000-05-01	RATIONALE: Azacitidine plus phenylbutyrate may help leukemia cells develop into normal white blood cells. PURPOSE: Phase I trial to study the effectiveness of combining azacitidine and phenylbutyrate in treating patients who have acute myeloid leukemia or myelodysplastic syndrome.
NCT00004871 ↗	Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome	Completed	Sidney Kimmel Comprehensive Cancer Center	Phase 1	2000-05-01	RATIONALE: Azacitidine plus phenylbutyrate may help leukemia cells develop into normal white blood cells. PURPOSE: Phase I trial to study the effectiveness of combining azacitidine and phenylbutyrate in treating patients who have acute myeloid leukemia or myelodysplastic syndrome.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Azacitidine

Condition Name

Chart
Table

Condition Name for Azacitidine
Intervention	Trials
Acute Myeloid Leukemia	141
Myelodysplastic Syndromes	97
Myelodysplastic Syndrome	83
Leukemia	42
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Azacitidine
Intervention	Trials
Leukemia	304
Leukemia, Myeloid, Acute	280
Myelodysplastic Syndromes	272
Leukemia, Myeloid	258
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Azacitidine

Trials by Country

Map
Table

Trials by Country for Azacitidine
Location	Trials
China	235
Japan	204
France	158
Canada	146
Germany	141
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Azacitidine
Location	Trials
Texas	184
California	124
New York	123
Illinois	89
Florida	82
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Azacitidine

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Azacitidine
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	60
Phase 2/Phase 3	8
[disabled in preview]	219
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Azacitidine
Clinical Trial Phase	Trials
Completed	163
Recruiting	149
Not yet recruiting	87
[disabled in preview]	72
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Azacitidine

Sponsor Name

Chart
Table

Sponsor Name for Azacitidine
Sponsor	Trials
National Cancer Institute (NCI)	98
Celgene Corporation	78
M.D. Anderson Cancer Center	60
[disabled in preview]	60
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Azacitidine
Sponsor	Trials
Other	508
Industry	459
NIH	100
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Medtronic

McKinsey

Johnson and Johnson

Moodys

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.